Applications Published 4 October 2001

Published: 16-Jun-2002

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).


The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).

  • Utilisation of nanoscalar organic filters which provide protection against UV light
    Cognis Deutschland 1137395*

  • Pharmaceutical preparation for inhalation of an opioid
    Pharmachemie 1137398*

  • Improvements in or relating to powders
    Vectura 1137399*

  • Compsns containing a peptide and polylactic acid suitable for preparing subcutaneous implants, with an extended release period
    Mediolanum Farmaceutica 1137400*

  • Administration of neurotrophic agents to the central nervous system
    Chiron Corp 1137401*

  • Phospholipid compsns
    Phares Pharmaceutical Research 1137402*

  • Sustained release tablet containing hydrocolloid and cellular ether
    Nostrum Pharmaceuticals 1137403*

  • Nanoparticulate core-shell systems and use thereof in pharmaceutical and cosmetic preparations
    BASF 1137404*

  • Active ingredient matrix in the form of a biologically resporbable porous non-woven made of collagen fibrils, method for the production and use thereof
    Aesculap 1137405*

  • Transdermal patch for delivering volatile liquids
    Elan Corp 1137406*

  • The process for manufacturing formulation of topical beta-blockers with improved efficacy
    Kharmar, Bakulesh Mafatal 1137407*

  • Agent for lowering endothelin levels
    Orion 1137408*

  • Novel 4-dedimethylaminotetracycline derivatives
    Collagenex Pharmaceuticals 1137410*

  • Palladium-substituted bacteriochlorophyll derivatives and use thereof
    Yeda Research & Development 1137411*

  • Substituted nitrogen heterocyclic compounds and theapeutic uses thereof
    American Biogenetic Sciences 1137412*

  • Non-peptide antagonists of GLP-1 receptor and methods of use
    Agouron Pharmaceuticals 1137413*

  • Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
    Davis, Bonnie 1137414*

  • MYT1 kinase inhibitors
    SmithKline Beecham 1137415*

  • Use of long-chain N-alkyl derivatives og deoxynojirimycin for the manufacture of a medicament for the treatment of glycolipid storage diseases
    GD Searle 1137416*

  • Use of selecred modulators of P2 purinoceptors for the prevention of damage and mortality caused by global cerebral ischaemia and ischaemia-reperfusion Consiglio Nazionale della
    Ricerche 1137417*

  • Methods and compsns for restoring conformational stability of a protein of the P53 family
    Pfizer 1137418*

  • Use of 1-amino-2-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid
    Gador; Rijksuniversiteit Leiden 1137419*

  • Method for obtaining and using a combination of a purine and a nitrogen monoxide donor for the treatment of sexual dysfunction
    Gorny, Philippe 1137420*

  • Use of fibroblasts or supernatants from fibroblasts for the supperssion of immune responses in transplantation
    Osiris Therapeutics 1137421*

  • Use of human prostate cell lines in cancer treatment
    Onyvax 1137423*

  • Oral administration of lactobacillus for the treatment and prevention of urogenital infection
    Urex Biotech 1137423*

  • Preparation which contains oligosaccharides and probiotics
    NV Nutrica 1137424*

  • Cancer treatment compsn and method using signal transduction modulators and natural plant essential oils
    Ecosmart Technologies 1137425*

  • Cancer treatment compsn and method using natural plant essential oils
    Ecosmart Technologies 1137426*

  • Cancer treatment compsn and method using natural plant essential oils with signal transduction modulators
    Ecosmart Technologies 1137427*

  • Method for simultaneous extraction of essential oils and antioxidants from Lamiaceae species and the extract products thereof
    Kemin Industries 1137428*

  • Bioflavonoids, anthocyanins and phenolic compounds from cherries for inhibiting inflammation
    Michigan State University 1137429*

  • Therapeutic agent for the suppression of snoring noises
    BioteCon Gesellschaft fur Biotechnologische Entwicklung und Consulting 1137430*

  • Pharmaceutical compsns containing insulin
    Provalis UK 1137431*

  • Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
    Eli Lilly 1137432*

  • New cancer treatments
    Onyvax 1137434*

  • Adjuvant comprising pulmonary sufactant
    ID-Lelystad; Stichting voor de Technische Wetenschappen; Nederlandse Organisatie voor Toegepast-natuurwetenschappelijk Onderzoek TNO 1137435*

  • Stimulation of T cells against self-anitgens using CTLA-4 blocking agents
    The Regents of the University of California 1137436*

  • Reagent and method for detecting a Crytosporidium parvum sporozoite antigen
    The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services 1137437*

  • Formulation with an improved therapeutic range, containing nucletide synthesis inhibitors
    Aventis Pharma Deutschland 1137438*

  • Stabilisation of Macrolides
    Novartis 1137439*

  • A stable product of isohexyl-naphthazarins with penta- and tetracyclic triterpenes
    Papgeorgiou, Vassilios 1137440*

  • Ion exchange tumour targeting
    Map 1137441*

  • Biologically active conjugates having a detectable reporter moiety and a method of identification of such derivatives
    Debio Recherche Pharmaceutique 1137442*

  • Magentic resonance tomography contract agent
    Goldham Pharma 1137443*

  • Method and apparatus for dispersing an air modifying agent
    Globol Chemicals 1137444*

  • Collagen hemostatic foam
    CR Bard 1137446*

  • A novel composite and its use
    Ylanen, Heimo; Aro, Hannu; Karlsson, Kaj; Hupa, Mikko 1137447*

  • A novel bioactive product and its use
    Ylanen, Heimo; Aro, Hannu; Karlsson, Kaj; Hupa, Mikko 1137448*

  • Skin composites
    The University of Sheffield 1137449*

  • Process for manufacture of L-DOPA ethyl ester
    Teva Pharmaceuticals 1137626*

  • Molecular scaffolds acting as templates comproding carbamate linkages
    La Jolla Pharmaceutical 1137628*

  • Continuous production of 2-acrylamido-2-methylpropane-sulphonic acid in a small reactor integrated with acrylic polymer fiber production
    The Lubrizol Company 1137629*

  • Reversible aqueous pH sensitive lipidising reagents, compsns and methods of use University of Southern
    California 1137630*

  • Thiourea inhibitors of herpes viruses
    American Home Products 1137632*

  • Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
    American Home Products 1137633*

  • Process for the synthesis of azetidinones
    Schering 1137634*

  • N-substituted 2-cyanopyrrolidines
    Novartis 1137635*

  • Process for the preparation of paroxetine maleate
    SmithKline Beecham 1137636*

  • N-(2-phenyl-4-piperidinylbutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin-1 (NK1) and/or neurokinin-2 (NK2) receptor antagonists
    AstraZeneca 1137637*

  • Isoquinoline derivatives
    SmithKline Beecham 1137638*

  • Cyclic hydrazine derivatives as TNF-alpha inhibitors
    F Hoffmann-La Roche 1137640*

  • Process for preparing pyradazin-3-on derivatives
    Sumitomo Chemical 1137641*

  • Bis-sulphonamides
    Actelion Pharmaceuticals 1137642*

  • Integrated method for producing epoxides from olefins
    Bayer 1137643*

  • Benzofuran derivatives, their preparation and use
    H Lundbeck 1137644*

  • Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group
    American Home Products 1137645*

  • Derivative of parxetine
    SmithKline Beecham 1137646*

  • Thiourea inhibitors of herpes viruses

    American Home Products 1137647*

  • Process for the production of trifluoromethyltropanone cyanohydrin
    Syngenta 1137648*

  • Process for the preparation of pyrimidone derivatives
    Syngenta Participations 1137649*

  • Process for producing deoiled phosphatides
    Archer-Daniels-Midland 1137650*

  • 1-hydroxy-3-sulphonoalkane-1,1-disphosphonous acids
    Bayer 1137651*

  • Conjugates comprising galactose alpha-1,3-galactosyl epitopes and emthods of using same
    La Jolla Pharmaceuticals 1137652*

  • Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same
    Laboratoires Negma 1137653*

  • Carbamate and carbazate ketolide antibiotics
    Pfizer 1137654*

  • Macrolide intermediates in the preparation of clarithromycin
    Biochemie 1137655*

  • 31 human secreted proteins
    Human Genome Sciences 1137656*

  • Methods of modulating tunour necrosis factor alpha-induced expresion of cell adhesion molecules
    Isis Pharmaceuticals 1137658*

  • Inhibition of angiogenesis by high molecular weight kininogen and peptides analogues thereof
    Temple University of the Commonwealth System of Higher Education 1137659*

  • 22S-hydroxycholesta-8,14-diene derivatives with meiosis regulating activity
    Akzo Nobel 1137660*

  • Procollagen C-proteinase inhibitors
    F Hoffmann-La Roche 1137661*

  • Pharmaceutical compsns comprising quinapril magnesium
    Sherman, Bernard Charles 1137662*

  • Purification of Echinocandin cyclopeptide compounds
    Eli Lilly 1137663*

  • Protein transduction system and methods of use thereof
    Washington University 1137664*

  • Cark protein and nucleic acid molecules and uses therefore
    Millennium Pharmaceuticals 1137665*

  • GLP-1 analogues
    Societe de Conseils de Recherches et d-Applications Scientifiques 1137666*

  • A method of detecting neuronal cell damage by quantification of MAP-2 levels in biological fluids
    Zemlan, Frank 1137668*

  • Squaric acid activated carrier usable for immobilisation of compounds containing amine groups
    Amersham Pharmacia Biotech 1137669*

  • Cross-linked process of carboxylated polysaccharides
    Aquisto 1137670*

  • Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compsns
    Jasper 1137671*
    • Companies:
    • Kemin
    See more

    • You may also like

    Applications published 5 December 2007

    Read more

    Trending Articles

    1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
    2. ChargePoint invest in a single-use manufacturing facility to expand product line The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
    3. N4 Pharma and SRI to target and treat previously unreachable human cells The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
    4. Berry Global invests to increase production capacity for healthcare products Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
    5. Innovation in generics: increased efficiency through peptide API synthesis expertise Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues

    Upcoming event

    Cleanroom Conference UK

    22–23 May 2024 | Exhibition | Birmingham, UK     See all

    You may also like

    Applications published 5 December 2007

    APPLICATIONS PUBLISHED 2 MARCH 2005

    The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492

    APPLICATIONS PUBLISHED 26 MAY 2004

    The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492

    APPLICATIONS PUBLISHED 5 NOVEMBER 2003

    The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T+43 1521 260 F+43 1 52126 4492
    Manufacturing

    Innovation in generics: increased efficiency through peptide API synthesis expertise

    Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
    Regulatory

    Broughton receives flexible scope ISO 17025 accreditation

    New certification allows accreditation without prior approval
    Research & Development

    N4 Pharma and SRI to target and treat previously unreachable human cells

    The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
    Subscribe now